{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:52:55Z","timestamp":1791874375246,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.dld.2023.04.010","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T07:58:46Z","timestamp":1682323126000},"page":"1214-1220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn's disease patients treated with biologics"],"prefix":"10.1016","volume":"55","author":[{"given":"Luca","family":"Degli Esposti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Daperno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Dovizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Sangiorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo Vicenzo","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"Secchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5018-490X","authenticated-orcid":false,"given":"Valentina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2023.04.010_bib0001","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/164_2016_122","article-title":"Inflammatory bowel disease: pathophysiology and current therapeutic approaches","volume":"239","author":"Abraham","year":"2017","journal-title":"Handb Exp Pharmacol"},{"issue":"10080","key":"10.1016\/j.dld.2023.04.010_bib0002","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.dld.2023.04.010_bib0003","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","article-title":"Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study","volume":"5","author":"Solberg","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2023.04.010_bib0004","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.dld.2023.04.010_bib0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10620-014-3368-z","article-title":"The economic and quality-of-life burden of Crohn's disease in Europe and the United States, 2000 to 2013: a systematic review","volume":"60","author":"Floyd","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.dld.2023.04.010_bib0006","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"9","key":"10.1016\/j.dld.2023.04.010_bib0007","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.dld.2014.04.014","article-title":"Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems","volume":"46","author":"Di Domenicantonio","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2023.04.010_bib0008","unstructured":"Degli Esposti L., Perrone V., Sangiorgi D., al. How many patients affected by Crohn's disease or ulcerative colitis not treated with biologic agents could be eligible for these therapies in Italy? Accepted Abstract at the Digestive Disease Week 2021. Available from: https:\/\/eposters.ddw.org\/ddw\/2021\/ddw-2021-virtual\/319705\/Last accessed: 06 April 2023"},{"issue":"1","key":"10.1016\/j.dld.2023.04.010_bib0009","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","article-title":"Ulcerative colitis and crohn's disease have similar burden and goals for treatment","volume":"18","author":"Le Berre","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.04.010_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211006669","article-title":"Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches","volume":"14","author":"Privitera","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"12","key":"10.1016\/j.dld.2023.04.010_bib0011","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.dld.2023.04.010_bib0012","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2023.04.010_bib0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000358135","article-title":"Have biologics changed the natural history of Crohn's disease?","volume":"32","author":"Mandel","year":"2014","journal-title":"Dig Dis"},{"issue":"5","key":"10.1016\/j.dld.2023.04.010_bib0014","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"4","key":"10.1016\/j.dld.2023.04.010_bib0015","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/pds.1549","article-title":"Using prescription registries to define continuous drug use: how to fill gaps between prescriptions","volume":"17","author":"Nielsen","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.dld.2023.04.010_bib0016","unstructured":"Patient Compliance: Sweetening the Pill. edited by Madhu Davies, Dr Faiz Kermani, Published December 28, 2006 by Routledge"},{"issue":"8","key":"10.1016\/j.dld.2023.04.010_bib0017","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/MEG.0000000000002183","article-title":"Who are the patients with Crohn's disease unsuitable to receive an anti-TNF\u03b1 therapy? Results from a survey of Italian physicians and literature review","volume":"33","author":"Caprioli","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2023.04.010_bib0018","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.dld.2019.02.004","article-title":"National patients\u2019 association representatives. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)","volume":"51","author":"Fiorino","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.dld.2023.04.010_bib0019","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000503859","article-title":"Persistence with biologic treatment in patients with inflammatory bowel disease: a German claims data analysis","volume":"102","author":"Mevius","year":"2021","journal-title":"Digestion"},{"issue":"4","key":"10.1016\/j.dld.2023.04.010_bib0020","doi-asserted-by":"crossref","first-page":"otab076","DOI":"10.1093\/crocol\/otab076","article-title":"Persistence, dosing, and other treatment patterns among crohn's disease patients initiating biologics in United States","volume":"3","author":"Teeple","year":"2021","journal-title":"Crohns Colitis 360"},{"issue":"4","key":"10.1016\/j.dld.2023.04.010_bib0021","doi-asserted-by":"crossref","first-page":"otab049","DOI":"10.1093\/crocol\/otab049","article-title":"Adalimumab, infliximab, and vedolizumab in treatment of ulcerative colitis: a long-term retrospective study in a tertiary referral center","volume":"3","author":"Gagnon","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"10.1016\/j.dld.2023.04.010_bib0022","doi-asserted-by":"crossref","unstructured":"Gagnon-Sanschagrin P., Sanon M., Davidson M., Willey C., Kachroo S., Hoops T., Naessens D., Guerin A., Cloutier M. Suboptimal treatment in patients with Crohn's disease using biologics. Accepted Abstract at the Digestive Disease Week 2023.","DOI":"10.1016\/S0016-5085(23)02253-9"},{"issue":"2","key":"10.1016\/j.dld.2023.04.010_bib0023","doi-asserted-by":"crossref","first-page":"otab011","DOI":"10.1093\/crocol\/otab011","article-title":"Persistence with biologic therapy and associated costs of patients with inflammatory bowel disease: a German retrospective claims data analysis","volume":"3","author":"Mahlich","year":"2021","journal-title":"Crohns Colitis 360"},{"issue":"6","key":"10.1016\/j.dld.2023.04.010_bib0024","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/00365521.2019.1627579","article-title":"Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab","volume":"54","author":"Ylisaukko-Oja","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.dld.2023.04.010_bib0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/CEOR.S66338","article-title":"Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study","volume":"6","author":"Degli Esposti","year":"2014","journal-title":"Clinicoecon Outcomes Res"},{"issue":"7","key":"10.1016\/j.dld.2023.04.010_bib0026","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1055\/a-0903-2938","article-title":"Real-world biologic treatment and associated cost in patients with inflammatory bowel disease. Behandlung und Kosten von Patienten mit CED in Deutschland","volume":"57","author":"Brandes","year":"2019","journal-title":"Z Gastroenterol"},{"issue":"2","key":"10.1016\/j.dld.2023.04.010_bib0027","doi-asserted-by":"crossref","first-page":"rkaa070","DOI":"10.1093\/rap\/rkaa070","article-title":"Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden","volume":"4","author":"Geale","year":"2020","journal-title":"Rheumatol Adv Pract"},{"issue":"8","key":"10.1016\/j.dld.2023.04.010_bib0028","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823005686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823005686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:23:24Z","timestamp":1761625404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865823005686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1590865823005686"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2023.04.010","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn's disease patients treated with biologics","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2023.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}